{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:05:38Z","timestamp":1770419138872,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["J16K10705"],"award-info":[{"award-number":["J16K10705"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.lungcan.2020.04.038","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:04:49Z","timestamp":1588719889000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses"],"prefix":"10.1016","volume":"145","author":[{"given":"Shunta","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tsunezuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10 Suppl 4","key":"10.1016\/j.lungcan.2020.04.038_bib0005","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.04.038_bib0010","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jtho.2017.06.072","article-title":"Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors","volume":"12","author":"Meurgey","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2020.04.038_bib0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2020.04.038_bib0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.04.038_bib0025","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2020.04.038_bib0035","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.038_bib0040","doi-asserted-by":"crossref","first-page":"542","DOI":"10.5858\/arpa.2016-0265-SA","article-title":"Whole slide imaging for analytical anatomic pathology and telepathology: practical applications today, promises, and perils","volume":"141","author":"Farris","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/his.13528","article-title":"Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma","volume":"73","author":"Koelzer","year":"2018","journal-title":"Histopathology"},{"issue":"21","key":"10.1016\/j.lungcan.2020.04.038_bib0050","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2020.04.038_bib0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.038_bib0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/PAS.0000000000001013","article-title":"Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores","volume":"42","author":"Gagne","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.04.038_bib0065","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/modpathol.2017.59","article-title":"PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability","volume":"30","author":"Brunnstrom","year":"2017","journal-title":"Mod. Pathol."},{"issue":"9 Suppl 2","key":"10.1016\/j.lungcan.2020.04.038_bib0070","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.04.038_bib0075","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2020.04.038_bib0080","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.038_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.suronc.2018.04.007","article-title":"Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma","volume":"27","author":"Okada","year":"2018","journal-title":"Surg. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.04.038_bib0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/modpathol.2012.40","article-title":"Micronodular thymic carcinoma with lymphoid hyperplasia: a clinicopathological and immunohistochemical study of five cases","volume":"25","author":"Weissferdt","year":"2012","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.04.038_bib0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0110","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol. Oncol. Res."},{"issue":"5","key":"10.1016\/j.lungcan.2020.04.038_bib0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.2000.00846.x","article-title":"Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas","volume":"36","author":"Kuo","year":"2000","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.038_bib0120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.lungcan.2020.04.038_bib0125","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/his.12512","article-title":"Type A and AB thymomas: histological features associated with increased stage","volume":"66","author":"Green","year":"2015","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.lungcan.2020.04.038_bib0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/PAS.0b013e31824fff50","article-title":"Is there a spectrum of cytologic atypia in type a thymomas analogous to that seen in type B thymomas? A pilot study of 13 cases","volume":"36","author":"Nonaka","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.038_bib0135","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cncr.10665","article-title":"New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.038_bib0140","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2020.04.038_bib0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer."},{"issue":"6","key":"10.1016\/j.lungcan.2020.04.038_bib0150","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.038_bib0155","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2020.04.038_bib0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.04.038_bib0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.anndiagpath.2018.03.012","article-title":"PD-L1 immuno-expression assay in thymomas: study of 84 cases and review of literature","volume":"34","author":"Guleria","year":"2018","journal-title":"Ann. Diagn. Pathol."},{"issue":"8","key":"10.1016\/j.lungcan.2020.04.038_bib0170","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.04.038_bib0175","first-page":"1361","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2020.04.038_bib0180","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 Immunohistochemistry comparability study in real-life Clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.04.038_bib0185","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.lungcan.2020.04.038_bib0190","article-title":"Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis","author":"Widmaier","year":"2019","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.04.038_bib0195","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cllc.2016.03.003","article-title":"A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study","volume":"17","author":"Planchard","year":"2016","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.038_bib0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jtho.2018.09.025","article-title":"Critical appraisal of programmed death ligand 1 reflex diagnostic testing: current standards and future opportunities","volume":"14","author":"Humphries","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.04.038_bib0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.3880483","article-title":"Expression of cytokeratin 5\/6 in epithelial neoplasms: an immunohistochemical study of 509 cases","volume":"15","author":"Chu","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2020.04.038_bib0210","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:40:14Z","timestamp":1759236014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220304086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":42,"alternative-id":["S0169500220304086"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.038","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}